Posts

Gene and Cell Therapies Enter a New Era: From Revolutionary Treatments to Market Realities

Image
The Great Cell and Gene Therapy Reckoning: From Revolutionary Promise to Industry Crossroads As personalized CRISPR therapies arrive and CAR-T cells target solid tumors, the field confronts manufacturing challenges and soaring costs The gene and cell therapy revolution that scientists have promised for decades is finally materializing—but not quite in the way many had envisioned. In 2025, the field stands at a pivotal crossroads, celebrating historic medical breakthroughs while grappling with formidable economic and manufacturing obstacles that threaten to limit patient access to these potentially life-saving treatments. A Landmark Year for Personalized Medicine In February 2025, an infant known as KJ became the world's first patient to receive a fully personalized CRISPR gene editing therapy at Children's Hospital of Philadelphia. Born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare metabolic disease, KJ received a customized base editing therapy del...
Post a Comment
Read more

Bone Health Alert: Why Men with Prostate Cancer Need Osteoporosis Screening

Image
Why brittle bones aren’t just a woman’s problem – Orange County Register Critical Information for Men on Hormone Therapy If you're being treated with androgen deprivation therapy (ADT) for prostate cancer, here's something your oncologist should be discussing with you: your bone health. A growing body of evidence shows that men—especially those on ADT—face serious but often overlooked risks of osteoporosis and life-threatening fractures. The Hidden Danger for Prostate Cancer Patients While osteoporosis has long been considered a "women's disease," the reality is starkly different for men with prostate cancer. About 1 in 5 men over age 50 will suffer an osteoporotic fracture in their remaining years, and men who do break a hip face worse outcomes than women, with 25% to 30% dying within a year. For men on ADT, the risk is even higher. Prostate cancer drugs are among the medications that significantly damage bone density. ADT works by lowering testosterone leve...
Post a Comment
Read more

New Target, New Hope: STEAP1 Therapies Show Promise for Advanced Prostate Cancer

Image
STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications | Prostate Cancer and Prostatic Diseases Multiple clinical trials now recruiting patients as research validates novel protein as effective treatment target Men with advanced prostate cancer have a new reason for optimism as multiple clinical trials targeting a protein called STEAP1 are now actively recruiting patients, offering access to cutting-edge therapies that are showing encouraging early results. STEAP1 (Six transmembrane epithelial antigen of prostate 1) is highly expressed in over 85% of prostate tumors while showing minimal presence in normal tissues, making it an ideal target for precision cancer treatment. Unlike some other prostate cancer targets, STEAP1 expression remains uniform even as the disease progresses, suggesting it could benefit the majority of patients with metastatic castration-resistant prostate cancer (mCRPC). Bispecific Antibody Shows Strong Clin...
Post a Comment
Read more

Telix Launches SOLACE Trial

Image
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain - Telix Pharmaceuticals New Bone Pain Treatment Enters Testing as Alternative to Proven Radium-223 Therapy TLX090 offers potential convenience advantages, but must prove it can match survival benefits of established treatment Telix Pharmaceuticals has initiated the SOLACE clinical trial, dosing the first patient with TLX090, an investigational radiopharmaceutical for metastatic bone pain. The Phase 1 study arrives as patients and physicians increasingly recognize both the promise and limitations of radium-223 (Xofigo®), the only bone-targeting therapy proven to extend survival in men with advanced prostate cancer. The Challenge: When Cancer Spreads to Bone Up to 90% of men with metastatic prostate cancer develop bone metastases, with approximately 400,000 new cases diagnosed annually across all cancer types. The resulting pain profoundly diminishes quality of life and mental health, yet current treatment options rem...
Post a Comment
Read more

When Cancers Share Genes—And When They Don't

Image
Multivariate GWAS reveals shared genetic etiology and pleiotropic loci across carcinomas | medRxiv New Study Reveals Complex Patterns with Critical Implications for Prostate Cancer Patients Massive genetic analysis of 429,000 cancer cases finds prostate cancer stands genetically apart from other major cancers—except for rare hereditary mutations like BRCA that link it to breast and ovarian cancer A groundbreaking international study has uncovered a genetic paradox with profound implications for prostate cancer patients: while analyzing common genetic variants across nine major cancer types, researchers found prostate cancer is genetically distinct from other epithelial cancers—so distinct it couldn't be incorporated into models that successfully explained genetic relationships among breast, lung, colorectal, and other cancers. Yet this finding coexists with a well-established clinical reality: families where breast and prostate cancer cluster together, linked by rare hereditary ...
Post a Comment
Read more

Age Over 80 and Prostate Cancer

Image
New Evidence Challenges "Too Old to Treat" Assumptions Recent research reveals elderly men with prostate cancer benefit significantly from active treatment—plus critical insights on sarcopenia, frailty assessment, and maintaining quality of life FOR IMMEDIATE RELEASE Informed Prostate Cancer Support Group Newsletter Groundbreaking research is overturning long-held assumptions about treating prostate cancer in men over 80, revealing that definitive therapy significantly improves survival while managing age-related health challenges becomes increasingly important for treatment success. Definitive Treatment Shows 50% Mortality Reduction A landmark analysis of nearly 20,000 men aged 80 or older with high-risk prostate cancer found that definitive local therapy—including surgery or radiation therapy with or without androgen deprivation therapy (ADT)—is associated with a 50% reduction in overall mortality compared with observation or ADT alone. The study recommends that lif...
Post a Comment
Read more